Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations
Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up ...
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...
Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Lowered to $26.00 at Barclays
Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...
American Association of Individual Investors8d
Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 13.89%
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 4.6% After Analyst Downgrade
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report)’s share price was down 4.6% on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00. UBS Group ...
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...